July 16, 2025 — Tevogen Bio Holdings Inc. (Nasdaq:TVGN) is doubling down on its AI capabilities following the successful launch of its proprietary PredicTcell™ platform. The company announced plans to expand its Tevogen.AI division to integrate real-world patient data, aiming to streamline clinical trial recruitment and speed time-to-market for its personalized T cell therapies.
Backed by Microsoft and Databricks, Tevogen.AI will use advanced algorithms to analyze electronic health records and identify eligible clinical trial participants based on detailed medical histories, demographics, and clinical profiles. The new initiative is designed to support Tevogen’s ExacTcell™ therapeutic pipeline.
“Tevogen.AI is a key part of our strategy to make personalized therapies both commercially viable and accessible,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “By removing trial enrollment bottlenecks, we can dramatically reduce development timelines and bring critical treatments to patients faster.”
The integration of AI-powered patient matching with target discovery from PredicTcell™ aims to enhance clinical trial efficiency, scalability, and inclusivity—critical challenges in drug development. The company sees this as a major step toward improving therapeutic outcomes and increasing shareholder value.
With this expansion, Tevogen positions itself at the forefront of using artificial intelligence to revolutionize drug development, offering a more cost-effective path to precision medicine and a foundation for long-term growth.
Follow Tevogen on InvestorsHub.com
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.